Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Efficacy and safety of nimotuzumab in addition to radiotherapy and temozolomide for cerebral glioblastoma: a phase II multicenter clinical trial.

Du XJ, Li XM, Cai LB, Sun JC, Wang SY, Wang XC, Pang XL, Deng ML, Chen FF, Wang ZQ, Chen FR, Zhang HH, Wang HY, Piedra P, Chen ZP, Lin J, Wu SX.

J Cancer. 2019 Jun 2;10(14):3214-3223. doi: 10.7150/jca.30123. eCollection 2019.

2.
3.

[Nimotuzumab in combination with chemotherapy for patients with malignant gliomas].

Yang QY, Shen D, Sai K, Mu YG, Jiang XB, Zhang XH, Chen ZP.

Zhonghua Zhong Liu Za Zhi. 2011 Mar;33(3):232-5. Chinese.

PMID:
21575527
4.

A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma.

Westphal M, Heese O, Steinbach JP, Schnell O, Schackert G, Mehdorn M, Schulz D, Simon M, Schlegel U, Senft C, Geletneky K, Braun C, Hartung JG, Reuter D, Metz MW, Bach F, Pietsch T.

Eur J Cancer. 2015 Mar;51(4):522-32. doi: 10.1016/j.ejca.2014.12.019. Epub 2015 Jan 20.

PMID:
25616647
5.

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ Jr, Mehta MP.

J Clin Oncol. 2013 Nov 10;31(32):4085-91. doi: 10.1200/JCO.2013.49.6968. Epub 2013 Oct 7.

6.

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M.

J Clin Oncol. 2010 Jun 1;28(16):2712-8. doi: 10.1200/JCO.2009.26.6650. Epub 2010 May 3.

PMID:
20439646
7.

Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.

Nitta Y, Shimizu S, Shishido-Hara Y, Suzuki K, Shiokawa Y, Nagane M.

Cancer Med. 2016 Mar;5(3):486-99. doi: 10.1002/cam4.614. Epub 2016 Jan 18.

8.

Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.

Ishikawa E, Muragaki Y, Yamamoto T, Maruyama T, Tsuboi K, Ikuta S, Hashimoto K, Uemae Y, Ishihara T, Matsuda M, Matsutani M, Karasawa K, Nakazato Y, Abe T, Ohno T, Matsumura A.

J Neurosurg. 2014 Sep;121(3):543-53. doi: 10.3171/2014.5.JNS132392. Epub 2014 Jul 4.

PMID:
24995786
9.

Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.

Lanzetta G, Campanella C, Rozzi A, Nappa M, Costa A, Fedele F, Innocenzi G, Gagliardi FM, Salvati M, Minniti G, Frati A, Frati L, Vecchione A.

Anticancer Res. 2003 Nov-Dec;23(6D):5159-64.

PMID:
14981983
10.

Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.

Chong DQ, Toh XY, Ho IA, Sia KC, Newman JP, Yulyana Y, Ng WH, Lai SH, Ho MM, Dinesh N, Tham CK, Lam PY.

BMC Cancer. 2015 Apr 11;15:255. doi: 10.1186/s12885-015-1191-3.

11.

Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment.

Kong XT, Nguyen NT, Choi YJ, Zhang G, Nguyen HN, Filka E, Green S, Yong WH, Liau LM, Green RM, Kaprealian T, Pope WB, Nghiemphu PL, Cloughesy T, Lassman A, Lai A.

Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1195-1203. doi: 10.1016/j.ijrobp.2018.01.001. Epub 2018 Jan 6. Erratum in: Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1289.

12.

Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.

Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, Sampson JH, McLendon RE, Herndon JE 2nd, Friedman HS.

J Neurooncol. 2009 Dec;95(3):393-400. doi: 10.1007/s11060-009-9937-x. Epub 2009 Jun 17.

13.

Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature.

Kebudi R, Cakir FB, Bay SB, Gorgun O, Altınok P, Iribas A, Agaoglu FY, Darendeliler E.

Childs Nerv Syst. 2019 Jan;35(1):83-89. doi: 10.1007/s00381-018-4001-9. Epub 2018 Nov 11.

PMID:
30417211
14.

Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial.

Liang J, E M, Wu G, Zhao L, Li X, Xiu X, Li N, Chen B, Hui Z, Lv J, Fang H, Tang Y, Bi N, Wang W, Zhai Y, Li T, Chen D, Zou S, Lu N, Perez-Rodríguez R, Zheng J, Wang L.

Onco Targets Ther. 2013 Nov 6;6:1589-96. doi: 10.2147/OTT.S50945. eCollection 2013.

15.

Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience.

Solomon MT, Miranda N, Jorrín E, Chon I, Marinello JJ, Alert J, Lorenzo-Luaces P, Crombet T.

Cancer Biol Ther. 2014 May;15(5):504-9. doi: 10.4161/cbt.28021. Epub 2014 Feb 12.

16.

Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.

Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.

PMID:
25434389
17.

EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide.

Cominelli M, Grisanti S, Mazzoleni S, Branca C, Buttolo L, Furlan D, Liserre B, Bonetti MF, Medicina D, Pellegrini V, Buglione M, Liserre R, Pellegatta S, Finocchiaro G, Dalerba P, Facchetti F, Pizzi M, Galli R, Poliani PL.

J Natl Cancer Inst. 2015 Mar 3;107(5). pii: djv041. doi: 10.1093/jnci/djv041. Print 2015 May.

PMID:
25739547
18.

Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide.

Minniti G, Salvati M, Arcella A, Buttarelli F, D'Elia A, Lanzetta G, Esposito V, Scarpino S, Maurizi Enrici R, Giangaspero F.

J Neurooncol. 2011 Apr;102(2):311-6. doi: 10.1007/s11060-010-0324-4. Epub 2010 Aug 5.

PMID:
20686820
19.

Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.

Butowski N, Chang SM, Lamborn KR, Polley MY, Pieper R, Costello JF, Vandenberg S, Parvataneni R, Nicole A, Sneed PK, Clarke J, Hsieh E, Costa BM, Reis RM, Hristova-Kazmierski M, Nicol SJ, Thornton DE, Prados MD.

Neuro Oncol. 2011 Dec;13(12):1331-8. doi: 10.1093/neuonc/nor130. Epub 2011 Sep 6.

20.

A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).

Kim HR, Jang JS, Sun JM, Ahn MJ, Kim DW, Jung I, Lee KH, Kim JH, Lee DH, Kim SW, Cho BC.

Oncotarget. 2017 Feb 28;8(9):15943-15951. doi: 10.18632/oncotarget.13056. Erratum in: Oncotarget. 2017 Aug 14;8(33):55766.

Supplemental Content

Support Center